Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 4/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9732996 | 0.84 | OPRM1 (0.44) | OPRM1OPRK1HTR2AHTR2CHTR2B | |
| SCHEMBL29122626 | 0.71 | HTR2A (0.39) | OPRM1OPRK1HTR2AHTR2CHTR2B | |
| SCHEMBL10511630 | 0.71 | PGR (0.41) | OPRM1OPRK1HTR2AHTR2CHTR2B | |
| SCHEMBL9733062 | 0.70 | HTR2A (0.38) | OPRM1OPRK1HTR2AHTR2CHTR2B | |
| SCHEMBL448438 | 0.69 | ESR1 (0.37) | ALDH1A1 | |
| SCHEMBL6493913 | 0.68 | PGR (0.47) | OPRM1OPRK1HTR2AHTR2CHTR2B | |
| SCHEMBL4439441 | 0.68 | GAA (0.34) | OPRM1OPRD1BACE1 | |
| SCHEMBL13600355 | 0.68 | GAA (0.34) | OPRM1OPRD1BACE1 | |
| SCHEMBL3638981 | 0.65 | HTR2A (0.46) | OPRM1OPRK1HTR2AHTR2CHTR2B | |
| SCHEMBL1576024 | 0.65 | HTR2A (0.46) | OPRM1OPRK1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | OPRM1 4752/4885OPRK1 2894/4885HTR2A 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.